Thrombus Treatment Companies | Market Research Future

Top Industry Leaders in the Thrombus Treatment Market

Thrombus Treatment Key Companies Latest Thrombus Treatment Companies Update

June 2023: The Lightning Bolt 7 technology, developed by Penumbra, Inc. PEN, is now available. It is used to quickly remove blood clots using modulated aspiration. Penumbra's latest innovation is a computer-assisted thrombectomy service that uses cutting-edge imaging and AI in conjunction with minimally invasive tools to treat vascular disorders including stroke. New aspiration technology and an enhanced microprocessor algorithm enable Lightning Bolt 7 technology to differentiate between a blood clot and normal blood flow. Modulated aspiration at the catheter's tip facilitates rapid and thorough clot removal. The technology is meant to provide a safety profile that, when coupled with the speed and efficiency of clot removal, will encourage an endovascular-first strategy prior to open surgery for a wider variety of situations.

May 2023: Asundexian, an experimental medication developed by Bayer, was recently awarded Fast Track Designation by the U.S. FDA for the treatment and prevention of stroke and systemic embolism in persons with atrial fibrillation (AF). This comes after asundexian received its first U.S. FDA Fast Track Designation in 2022, this time for the treatment of patients who have had a non-cardioembolic ischemic stroke. Blood coagulation involves the conversion of a protein called Factor XI into an active enzyme called Factor XIa. By selectively inhibiting FXIa, we can prevent the production of pathological thrombi while sparing the recovery of physiological arterial wall damage. The antithrombotic drug asundexian is now being studied for its potential as an enhanced therapy option in thrombosis prevention.

List of Thrombus Treatment Key companies in the market